 | |
| Clinical data | |
|---|---|
| Trade names | Netromycin |
| Other names | 1-N-Ethylsisomicin |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a605011 |
| Routes of administration | Topical |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | ~0% |
| Eliminationhalf-life | 2.5 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.054.661 |
| Chemical and physical data | |
| Formula | C21H41N5O7 |
| Molar mass | 475.587 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Netilmicin (1-N-ethylsisomicin) is a semisyntheticaminoglycosideantibiotic, and a derivative ofsisomicin, produced byMicromonospora inyoensis. Aminoglycoside antibiotics have the ability to kill a wide variety ofbacteria. Netilmicin is not absorbed from thegut and is therefore only given by injection or infusion. It is only used in the treatment of seriousinfections particularly those resistant togentamicin.
It was patented in 1973 and approved for medical use in 1981.[2] It was approved for medical use in the UK in December 2019, for the treatment of external infections of the eye.[3] It is on theWorld Health Organization's List of Essential Medicines.[4]
According to theBritish National Formulary (BNF), netilmicin has similar activity to gentamicin, but lessototoxicity in those needing treatment for longer than 10 days. Netilmicin is active against a number of gentamicin-resistantGram-negative bacteria but is less active againstPseudomonas aeruginosa than gentamicin ortobramycin.[citation needed]
